BackTurning Point Therapeutics Overview

Turning Point Therapeutics Research & Development

Get informed when a big investor buys or sells

+ Follow

Quarterly R&D Expenses

$86.79M
94.37% YoY

As of Jun 30, 2022

Annual R&D Expenses (TTM)

$248.90M
63.32% YoY

Trailing 12 months ending Jun 30, 2022

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Turning Point Therapeutics (TPTX) FAQ

Stockcircle tracks research & development for Turning Point Therapeutics (TPTX), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Research & Development page is built for Turning Point Therapeutics's historical R&D spending trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use R&D spending as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main TPTX overview so you can move from this figure to the surrounding analysis quickly.